Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation

Oncology

Volumn 79, Issue 1-2, 2010, Pages 62-66

  Kim, Richard ^a   El Gazzaz, Galal ^b   Tan, Ann ^a   Elson, Paul ^b   Byrne, Michael ^a   Chang, Young Doo ^b   Aucejo, Federico ^b  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Hepatocellular carcinoma; Orthotopic liver transplantation; Sorafenib

Indexed keywords

SORAFENIB;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG SAFETY; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; MEDICAL RECORD REVIEW; MUCOSA INFLAMMATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RASH; SIDE EFFECT; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MEDICAL RECORDS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROTEIN KINASE INHIBITORS; PYRIDINES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 78149315368     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000319548     Document Type: Article

References (22)

1. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533-543.
2. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917.
3. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699.
4. Yao FY, Kinkhabwala M, LaBerge JM, Bass NM, Brown R Jr, Kerlan R, Venook A, Ascher NL, Emond JC, Roberts JP: The impact of preoperative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant 2005; 5: 795-804.
5. Silva M, Moya A, Berenguer M, Sanjuan F, Lopez-Andujar R, Pareja E, Torres-Quevedo R, Aguilera V, Montalva E, De Juan M, Mattos A, Prieto M, Mir J: Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma. Liver Transpl 2008; 14: 1449-1460.
6. Kim R, Tan A, Estfan B, Aucejo F: Adjuvant treatment after orthotopic liver transplantation: is it really necessary? Oncology 2009; 23: 1276-1281.
7. Lee JO, Kim DY, Lim JH, Seo MD, Yi HG, Oh DY, Im SA, Kim TY, Bang YJ: Palliative chemotherapy for patients with recurrent hepatocellular carcinoma after liver transplantation. J Gastroenterol Hepatol 2009; 24: 800-805.
8. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
9. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
10. Sabatini DM: Motor and cancer: insights into a complex relationship. Nat Rev Cancer 2006; 6: 729-734.
11. Zhou J, Wang Z, Wu ZQ, Qiu SJ, Yu Y, Huang XW, Tang ZY, Fan J: Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria. Transplant Proc 2008; 40: 3548-3553.
12. Worns MA, Weinmann A, Pfingst K, Schulte- Sasse C, Messow CM, Schulze-Bergkamen H, Teufel A, Schuchmann M, Kanzler S, Duber C, Otto G, Galle PR: Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol 2009; 43: 489-495.
13. Pinter M, Sieghart W, Graziadei I, Vogel W, Maieron A, Konigsberg R, Weissmann A, Kornek G, Plank C, Peck-Radosavljevic M: Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 2009; 14: 70-76.
14. Shin WY, Suh KS, Lee HW, Kim J, Kim T, Yi NJ, Lee KU: Prognostic factors affecting survival after recurrence in adult living donor liver transplantation for hepatocellular carcinoma. Liver Transpl 2010; 16: 678-684.
15. Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B, Cabellos L, Savic R, Hoshida Y, Lim KH, Melgar-Lesmes P, Yea S, Peix J, Deniz K, Fiel MI, Thung S, Alsinet C, Tovar V, Mazzaferro V, Bruix J, Roayaie S, Schwartz M, Friedman SL, Llovet JM: Ras pathway activation in hepatocellular carcinoma and anti- tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol 2009; 51: 725-733.
16. Carracedo A, Baselga J, Pandolfi PP: Deconstructing feedback-signaling networks to improve anticancer therapy with MTORC1 inhibitors. Cell Cycle 2008; 7: 3805-3809.
17. Bhoori S, Toffanin S, Sposito C, Germini A, Pellegrinelli A, Lampis A, Mazzaferro V: Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle. J Hepatol 2010; 52: 771-775.
18. Feun LG LD, Moon J, et al: Sorafenib in hepatocellular carcinoma (HCC) patients after liver transplantation. Proc Am Soc Clin Oncol 2009:abstr. e15579.
19. Valdivieso A, Bustamante J, Gastaca M, Uriarte JG, Ventoso A, Ruiz P, Fernandez JR, Pijoan I, Testillano M, Suarez MJ, Montejo M, Ortiz de Urbina J: Management of hepatocellular carcinoma recurrence after liver transplantation. Transplant Proc 2010; 42: 660-662.
20. Yoon DH, Ryoo BY, Ryu MH, Lee SG, Hwang S, Suh DJ, Lee HC, Kim TW, Ahn CS, Kim KH, Moon DB, Kang YK: Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. Jpn J Clin Oncol 2010; 40: 768-773.
21. Yeganeh M, Finn RS, Saab S: Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib. Am J Transplant 2009; 9: 2851-2854.
22. Kim R, Aucejo F: Radiologic complete response with sirolimus and sorafenib in a hepatocellular carcinoma patient who relapsed after orthotopic liver transplantation. J Gastrointest Cancer 2010; DOI:10.1007/s12029- 010-9196-2.